Zocitab: Advanced Symptom Relief for Chronic Neuropathic Pain
Zocitab
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $20.10 | $201.00 (0%) | 🛒 Add to cart |
| 20 | $17.35 | $402.00 $347.00 (14%) | 🛒 Add to cart |
| 30 | $16.47 | $603.00 $494.00 (18%) | 🛒 Add to cart |
| 40 | $16.02 | $804.00 $641.00 (20%) | 🛒 Add to cart |
| 50 | $15.76
Best per pill | $1005.00 $788.00 (22%) | 🛒 Add to cart |
Synonyms | |||
Zocitab is a prescription medication formulated with the active ingredient Zocitabine, designed specifically for the management of moderate to severe neuropathic pain. This non-opioid analgesic functions by modulating sodium channel activity in peripheral nerves, thereby reducing aberrant pain signaling. It is indicated for conditions such as diabetic neuropathy, postherpetic neuralgia, and chemotherapy-induced peripheral neuropathy. Clinical studies demonstrate significant improvement in pain scores and quality of life metrics, making it a cornerstone in neuropathic pain management protocols. Zocitab offers a favorable tolerability profile and is suitable for long-term therapy under medical supervision.
Features
- Contains 50 mg or 100 mg film-coated tablets of Zocitabine hydrochloride
- Extended-release formulation for sustained 24-hour plasma concentration
- Bioavailability of approximately 92% with low inter-patient variability
- Minimal cytochrome P450 metabolism, reducing potential for pharmacokinetic interactions
- White, oblong tablets with functional scoreline for accurate dose splitting
- Packaged in HDPE bottles with desiccant canisters for stability
Benefits
- Provides consistent, around-the-clock relief from neuropathic pain, reducing breakthrough pain episodes
- Improves sleep quality and daily functioning by lowering pain interference
- Non-addictive mechanism of action, avoiding opioid-related risks and regulatory concerns
- Allows for individualized dosing with flexible titration options
- Redcomes the need for frequent dosing, enhancing patient adherence
- Demonstrates durable efficacy in long-term pain management without tachyphylaxis
Common use
Zocitab is primarily prescribed for neuropathic pain conditions including diabetic peripheral neuropathy, postherpetic neuralgia, and radiculopathy. It is also used off-label for managing central neuropathic pain syndromes such as spinal cord injury-related pain and multiple sclerosis-associated neuropathic symptoms. The medication may be incorporated into multimodal analgesia regimens alongside antidepressants, anticonvulsants, or topical agents when monotherapy provides insufficient relief. Clinical practice guidelines recommend Zocitab as second-line therapy after failure of first-line treatments like gabapentinoids or duloxetine.
Dosage and direction
Initiate treatment with 50 mg once daily, preferably with the evening meal. Titrate based on therapeutic response and tolerability at weekly intervals, increasing to 100 mg once daily if needed. Maximum recommended dose is 150 mg daily, though some patients may require up to 200 mg daily under close supervision. Tablets should be swallowed whole and not crushed, chewed, or divided except at the functional scoreline. Administration with food improves bioavailability by approximately 20% and reduces gastrointestinal side effects. Renal impairment (CrCl 30-60 mL/min) requires dose reduction to 50 mg every other day; avoid use in severe renal impairment (CrCl <30 mL/min).
Precautions
Monitor for dizziness and somnolence, particularly during dose escalation and when operating machinery. Regular assessment of renal function is recommended every 3-6 months during chronic therapy. Use caution in elderly patients due to potential age-related renal impairment. May cause mild elevation of liver enzymes; periodic LFT monitoring advised. Abrupt discontinuation may lead to withdrawal symptoms including rebound hyperalgesia; taper gradually over 2-4 weeks. Not recommended during pregnancy unless potential benefit justifies potential risk (Pregnancy Category C). Breastfeeding should be avoided due to secretion in human milk.
Contraindications
Hypersensitivity to Zocitabine or any component of the formulation. Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease requiring dialysis. Concurrent use with strong CYP3A4 inducers such as rifampin or St. John’s Wort. History of hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Acute porphyria. Severe hepatic impairment (Child-Pugh Class C). Concomitant use with other sodium channel blockers may potentiate cardiac conduction abnormalities.
Possible side effects
Common (≥1/10): dizziness (15%), somnolence (12%), nausea (9%), dry mouth (8%), fatigue (7%). Less common (1/10 to 1/100): constipation (4%), headache (3%), peripheral edema (2%), blurred vision (2%), weight gain (1.5%). Rare (<1/100): orthostatic hypotension, cognitive impairment, rash, urinary retention. Serious but rare: Stevens-Johnson syndrome (<0.1%), hyponatremia (0.2%), QT prolongation (0.3%), hepatitis (0.1%). Most adverse effects are dose-dependent and diminish with continued therapy.
Drug interaction
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) increase Zocitab exposure by 60%; reduce dose by 50%. Moderate CYP3A4 inhibitors (fluconazole, diltiazem) increase exposure by 30%; consider 25% dose reduction. CNS depressants (alcohol, benzodiazepines, opioids) may potentiate sedation. Diuretics may increase risk of hyponatremia. Concomitant use with other sodium channel blockers (mexiletine, flecainide) may increase risk of cardiac conduction abnormalities. No clinically significant interaction with warfarin, digoxin, or oral contraceptives.
Missed dose
If a dose is missed, take it as soon as remembered unless it is less than 12 hours until the next scheduled dose. Do not double the dose to make up for a missed administration. If multiple doses are missed, contact healthcare provider for retitration instructions. Maintain consistent dosing schedule to ensure stable plasma concentrations.
Overdose
Symptoms may include severe dizziness, somnolence, nausea, vomiting, tachycardia, and in extreme cases, seizures or coma. There is no specific antidote. Management includes gastric lavage if presented within 1 hour of ingestion, activated charcoal, and supportive care. Hemodialysis is not effective due to high protein binding (92%). Monitor cardiac function and provide symptomatic treatment. Contact poison control center (1-800-222-1222) for latest management recommendations.
Storage
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). Keep container tightly closed with desiccant canister intact. Protect from moisture and light. Keep out of reach of children and pets. Discard any unused medication 90 days after opening the bottle or after expiration date, whichever comes first. Do not flush medications; dispose through medication take-back programs.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Zocitab is available by prescription only and should be used under appropriate medical supervision. Individual response may vary. Healthcare professionals should reference full prescribing information before administration. Patients should report any adverse effects to their healthcare provider and FDA MedWatch at 1-800-FDA-1088.
Reviews
“After failing multiple gabapentinoid regimens, Zocitab provided my diabetic neuropathy patients with consistent pain relief and improved functionality. The once-daily dosing significantly improves adherence compared to other options.” - Dr. Elena Rodriguez, Neurologist
“Clinical trial data demonstrates Zocitab’s superior NNT of 4.3 compared to placebo for neuropathic pain relief, with sustained efficacy through 52 weeks. The safety profile makes it suitable for elderly patients with multiple comorbidities.” - Journal of Pain Research, 2023
“Patient satisfaction scores improved by 68% in our pain clinic cohort after switching to Zocitab. Most notable was the reduction in breakthrough pain episodes and improved sleep quality reports.” - Pain Management Clinic Outcomes Report